If datopotamab deruxtecan (Dato-DXd) is approved for first-line metastatic TNBC, it could significantly influence clinical practice by providing an effective option for patients, particularly those ineligible for immunotherapy or with PD-L1–negative disease.
Pharmacists play a critical role in educating patients about potential side effects, monitoring for early signs of toxicity, and coordinating supportive care measures, including growth factor support for hematologic events.
Studying antibody–drug conjugates (ADCs) in patients ineligible for immunotherapy addresses a critical unmet need in PD-L1–negative metastatic TNBC, where targeted treatment options are limited.
If sacituzumab govitecan (SG) is approved for first-line metastatic TNBC, it could meaningfully shift clinical practice by providing an effective option for patients ineligible for immunotherapy or with PD-L1–negative disease.
In the final segment, the panelists bring together the major insights from across the series, highlighting the most clinically meaningful data from monarchE, NATALEE, and VIKTORIA-1 and what these findings mean for the evolving role of CDK4/6 inhibitors in both early-stage and metastatic HR+ breast cancer.
In this segment, the experts turn their attention to metastatic HR+/HER2– breast cancer, examining the first results from the VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib.
Pharmacists explore new breast cancer therapies and management strategies, enhancing patient care and treatment outcomes at SABCS.
Because ASCENT-03 allowed crossover and more than half of patients received subsequent therapy, overall survival is unlikely to show a statistically significant difference, even if a clinical benefit exists.
The ASCENT-03 trial, presented at ESMO and published in NEJM, evaluated sacituzumab govitecan (SG) versus physician’s-choice chemotherapy—including paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin—in patients with metastatic TNBC who were either PD-L1–negative or not candidates for immunotherapy.
In this segment, the experts dive into the monarchE subanalysis evaluating how Ki-67 levels before and after neoadjuvant chemotherapy inform prognosis and treatment planning for high-risk HR+, HER2– early breast cancer.
In this segment, the panel unpacks the 5-year results from the NATALEE trial, which evaluated ribociclib plus a nonsteroidal aromatase inhibitor in early HR+/HER2– breast cancer.
SABCS showcases emerging trends in breast cancer treatment, emphasizing pharmacists' vital role in medication management and patient care strategies.
If SG plus pembrolizumab becomes approved in the first-line metastatic TNBC setting, many clinicians anticipate shifting practice patterns to favor this regimen, given its promising efficacy.
From a pharmacologic standpoint, the adverse events associated with sacituzumab govitecan (SG)—particularly neutropenia and diarrhea—are consistent with the mechanism of its payload.
New findings reveal a modest overall survival benefit of abemaciclib in early breast cancer, highlighting the importance of ongoing patient education and treatment strategies.
Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.
In clinical practice, the approach to G-CSF use with sacituzumab govitecan (SG) is typically individualized based on patient-specific risk factors and prior tolerance.
This section compares the adverse-event patterns of SG plus pembrolizumab versus chemotherapy plus pembrolizumab, emphasizing differences in hematologic and non-hematologic toxicities that inform clinical monitoring.
This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.
This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.
The FDA is modernizing its approach to drug development and optimization.
Published: November 26th 2025 | Updated:
